Year: 2021

– At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 – – With co-administration of AAV8 empty capsids and ImmTOR, Selecta observed dose-dependent response to ImmTOR with a safety profile in line with prior human studies – – Based on these data Selecta intends to rapidly advance its wholly owned gene therapy pipeline, and continue to selectively evaluate gene therapy partnership opportunities utilizing ImmTOR – – Selecta to host conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses,...

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed Chairman of the Board BLACKSBURG, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) — Landos Biopharma Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and Chief Executive Officer, effective immediately. Tim M. Mayleben, a member of the Landos Board, has been appointed Interim President and CEO. Chris Garabedian, also a Landos Director, has been appointed Chairman of the Board. Dr. Bassaganya-Riera will serve as an advisor to the Company to ensure a smooth...

VANCOUVER, British Columbia, Nov. 08, 2021 (GLOBE NEWSWIRE) — Great Quest Fertilizer Ltd (TSXV:GQ) (“Great Quest” or the “Company”) announces that Mr. Mama Tapo joins the Board of Directors of the Company, effective immediately. Mr. Mama Tapo has worked with Great Quest in the capacity of a local liaison in Mali and strategic advisor on the Company’s governmental relations since 2009. Mama Tapo brings more the 40 years of experience in business administration and strategic planning to Great Quest. He has dedicated his life and career to the development of his country and support for his countrymen. Professionally, he has worked as a senior advisor to the Malian government where he oversaw the coordination of its World Bank programs and designed a leadership training development program for USAID. He was formerly the Malian director...

DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in November: Cowen 5th Annual IO Next SummitMonday, November 15, 2021Session Time: 4:45 PM – 5:05 PM ETLive Session Link: https://wsw.com/admin/link/presenter.aspx?418616172 Jefferies Global Healthcare Conference (London)Thursday, November 18, 2021Session Time: 3:00 AM ETSession Link: https://wsw.com/webcast/jeff201/til/1696446/. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation. Both sessions can also be accessed by visiting...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 08, 2021 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan” or the “Trust”) (TSX: REI.UN) today announced that it has closed its previously announced offering of $450 million principal amount of Series AE senior unsecured debentures (the “Debentures”). The Debentures are RioCan’s third Green Bond. Issued at par, the Debentures carry an annual coupon rate of 2.829% with a seven-year term, maturing on November 8, 2028. The Debentures were sold on a private placement basis in certain provinces of Canada. The offering was made on an agency basis by a syndicate of agents co-led by TD Securities, RBC Capital Markets, BMO Capital Markets, CIBC Capital Markets and Scotia Capital Inc.   The Series AE Debentures were issued as Green...

Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled dry powder version of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA) (NCT #04576325). This study assessed the safety and tolerability of patients with mild to moderate asthma, a population at high...

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference on Thursday, November 18th at 3:00am EST Evercore ISI HealthCONx Conference on Tuesday, November 30th at 10:30am EST Access to the live webcast of these events, as well as an archived recording, will be available under the “Events” tab on the investor relations section of the Werewolf Therapeutics website at: https://investors.werewolftx.com/news-and-events/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an...

MONACO, Nov. 08, 2021 (GLOBE NEWSWIRE) — Eneti Inc. (NYSE:NETI) (the “Company”) announced today that it intends to offer, issue and sell to the public $200 million of shares of its common stock, par value $0.01 per share (the “Common Shares”), through an underwritten public offering (the “Offering”). The net proceeds of the Offering are expected to be used for general corporate purposes, including the funding of the Company’s wind turbine installation vessel newbuilding program consisting of one contracted newbuilding vessel, one optional newbuilding vessel and one proposed Jones Act compliant newbuilding vessel. As part of the Offering, Scorpio Holdings Limited, a related party of the Company, has expressed an interest to purchase Common Shares at the public offering price with a value of at least $30.0 million. Citigroup, DNB...